Novartis Puts A Halt To Drug Price Increases While Awaiting More On Trump's Blueprint

Novartis joined Pfizer in agreeing to hold off on any further US drug price increases this year, saying the decision was prudent in the current environment. On Trump's drug pricing blueprint, Novartis said it is carefully monitoring how policy evolves this year before charting a course for 2019.

Basel, Switzerland - 27 August, 2016: sign on the wall of a Novartis building. Novartis International AG is a Swiss pharmaceutical company based in Basel, Switzerland.

Novartis AG is the second big pharma behind Pfizer Inc. to declare that it will hold off on raising the prices of any drugs in the US for the remainder of the year, as it awaits clarity on evolving drug policy.

CEO Vas Narasimhan announced the decision during the company's second quarter earnings call July 18 in which the company said it delivered strong sales of new drugs like Cosentyx (secukinumab) and the heart failure drug Entresto (sacubitril/valsartan), but also

Novartis Puts A Halt To Drug Price Increases While Awaiting More On Trump's Blueprint

More from Pricing Debate

More from Market Access